Masafumi Noguchi, Susumu Kohno, Anna Pellattiero, Yukino Machida, Keitaro Shibata, Norihito Shintani, Takashi Kohno, Noriko Gotoh, Chiaki Takahashi, Atsushi Hirao, Luca Scorrano and Atsuko Kasahara : Inhibition of the mitochondria-shaping protein Opa1 restores sensitivity to Gefitinib in a lung adenocarcinomaresistant cell line., Cell Death & Disease, Vol.14, No.4, 2023.
(Summary)
Drug resistance limits the efficacy of chemotherapy and targeted cancer treatments, calling for the identification of druggable targets to overcome it. Here we show that the mitochondria-shaping protein Opa1 participates in resistance against the tyrosine kinase inhibitor gefitinib in a lung adenocarcinoma cell line. Respiratory profiling revealed that oxidative metabolism was increased in this gefitinib-resistant lung cancer cell line. Accordingly, resistant cells depended on mitochondrial ATP generation, and their mitochondria were elongated with narrower cristae. In the resistant cells, levels of Opa1 were increased and its genetic or pharmacological inhibition reverted the mitochondrial morphology changes and sensitized them to gefitinib-induced cytochrome c release and apoptosis. In vivo, the size of gefitinib-resistant lung orthotopic tumors was reduced when gefitinib was combined with the specific Opa1 inhibitor MYLS22. The combo gefitinib-MYLS22 treatment increased tumor apoptosis and reduced its proliferation. Thus, the mitochondrial protein Opa1 participates in gefitinib resistance and can be targeted to overcome it.
(Keyword)
Neoplasm / Drug Resistance / Lung Neoplasms / Protein Kinase Inhibitors / mitochondria / Lung / cell proliferation and differentiation / apoptosis / Antineoplastic Agents / GTP Phosphohydrolases
Margherita Zamberlan, Amandine Boeckx, Florian Muller, Federica Vinelli, Olivier Ek, Caterina Vianello, Emeline Coart, Keitaro Shibata, Aurélie Christian, Francesca Grespi, Marta Giacomello, Ingrid Struman, Luca Scorrano and Stéphanie Herkenne : Inhibition of the mitochondrial protein Opa1 curtails breast cancer growth., Journal of Experimental & Clinical Cancer Research, Vol.41, No.1, 2022.
(Summary)
Our data show that targeted inhibition of the mitochondrial fusion protein OPA1 curtails TNBC growth and nominate OPA1 as a druggable target in TNBC.
Naoki Hosokawa, Masahiro Kuragano, Atsuki Yoshino, Keitaro Shibata, P Taro Q Uyeda and Kiyotaka Tokuraku : Unidirectional cooperative binding of fimbrin actin-binding domain 2 to actin filament., Biochemical and Biophysical Research Communications, Vol.552, 59-65, 2021.
(Summary)
Fimbrin forms bundles of parallel actin filaments in filopodia, but it remains unclear how fimbrin forms well-ordered bundles. To address this issue, we focused on the cooperative interaction between the actin-binding domain of fimbrin and actin filaments. First, we loosely immobilized actin filaments on a glass surface via a positively charged lipid layer and observed the binding of GFP-fused actin-binding domain 2 of fimbrin using fluorescence microscopy. The actin-binding domain formed low-density clusters with unidirectional growth along actin filaments. When the actin filaments were tightly immobilized to the surface by increasing the charge density of the lipid layer, cluster formation was suppressed. This result suggests that the propagation of cooperative structural changes of actin filaments evoked by binding of the actin-binding domain was suppressed by a strong physical interaction with the glass surface. Interestingly, binding of the fimbrin actin-binding domain shortened the length of loosely immobilized actin filaments. Based on these results, we propose that fimbrin-actin interactions accompanied by unidirectional long-range allostery help the formation of well-ordered parallel actin filament bundles.
(Keyword)
Actin / Actin binding protein / Dictyostelium discoideum
Kei Saito, Takashi Murayama, Tomone Hata, Takuya Kobayashi, Keitaro Shibata, Saiko Kazuno, Tsutomu Fujimura, Takashi Sakurai and Y Yoko Toyoshima : Conformational diversity of dynactin sidearm and domain organization of its subunit p150., Molecular Biology of the Cell, Vol.31, No.12, 1218-1231, 2020.
(Summary)
Dynactin is a principal regulator of the minus-end directed microtubule motor dynein. The sidearm of dynactin is essential for binding to microtubules and regulation of dynein activity. Although our understanding of the structure of the dynactin backbone (Arp1 rod) has greatly improved recently, structural details of the sidearm subcomplex remain elusive. Here, we report the flexible nature and diverse conformations of dynactin sidearm observed by electron microscopy. Using nanogold labeling and deletion mutant analysis, we determined the domain organization of the largest subunit p150 and discovered that its coiled-coil (CC1), dynein-binding domain, adopted either a folded or an extended form. Furthermore, the entire sidearm exhibited several characteristic forms, and the equilibrium among them depended on salt concentrations. These conformational diversities of the dynactin complex provide clues to understanding how it binds to microtubules and regulates dynein.
Keitaro Shibata and Shigenobu Yonemura : 上皮極性形成におけるアクチンリング構造の機能解析, 日本細胞生物学会大会, Jun. 2023.
3.
Keitaro Shibata, Kohki Ishida, Chihori Asano and Shigenobu Yonemura : 上皮シート張力の創傷閉鎖における機能に関するレオロジー測定, 日本メカノバイオロジー学会 第7回 学術総会 (北海道大学), Mar. 2023.
4.
Keitaro Shibata and Shigenobu Yonemura : アクチンフィラメントの流れと上皮細胞頂底極性形成との関係, The74th Annual Meeting of the Japan Society for Cell Biology, Jun. 2022.
5.
Keitaro Shibata, 佐川 美咲, 小嶋 寛明, Shigenobu Yonemura and 古田 健也 : Increasing velocity of single-molecule kinesin movement in vitro, The73th Annual Meeting of the Japan Society for Cell Biology, Jul. 2021.
Keitaro Shibata, Sagawa Misaki, Kojima Hiroaki and Furuta Ken'ya : Increasing speed of single-molecule kinesin movement in vitro, 第58回日本生物物理学会年会, Sep. 2020.